Frontier Medicines
SOUTH SAN FRANCISCO, Calif. and BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Frontier Medicines Corporation, a precision medicine institution seeking to unlock the proteome to beforehand breakthroughs against different undruggable disease-causing targets, contiguous announced the 2nd and 3rd programs nether the company's planetary concern with AbbVie person precocious into pb generation. These programs harness caller E3 Ligases for targeted macromolecule degradation, done the find of tiny molecules from The Frontier™ Platform.
"Our collaboration with Frontier is continuing to marque advancement against difficult-to-drug macromolecule targets," said Jonathon Sedgwick, Ph.D., vice president and planetary head, Discovery Research, AbbVie. "Two years into our partnership, Frontier's exertion is showing important advances successful the drugging of antecedently inaccessible biology, this clip towards enabling binders for caller E3 ligases, with the imaginable to beryllium applied to the find and improvement of caller and amended therapeutic options for patients."
Started successful 2020, the nonsubjective of the planetary concern is to discover, develop, and commercialize a pipeline of innovative tiny molecule therapeutics against definite high-interest, difficult-to-drug macromolecule targets.
"We are excited that our team's work, with enactment from AbbVie, has resulted successful accessing 2 antecedently undruggable E3 Ligases for targeted macromolecule degradation, and each programme has the imaginable to thrust caller therapeutic opportunities for patients," said Chris Varma, Ph.D., Frontier's co-founder, chairman, and CEO. "Our transportation of 3 programs into pb procreation further validates The Frontier™ Platform's quality to systematically observe and present tiny molecules to cause undruggable targets. We look guardant to progressing these caller breakthrough discoveries to assistance beforehand transformative attraction for patients."
About Frontier and AbbVie Partnership
Under the partnership, the companies volition collaborate connected the probe and pre-clinical improvement of programs directed to caller E3 ligases, and definite immunology and oncology targets. AbbVie volition reimburse Frontier's R&D costs done defined stages of pre-clinical development. Upon palmy completion, AbbVie volition presume afloat work for planetary improvement and commercialization activities and costs for the programs. Frontier volition clasp an enactment to stock improvement activities and expenses for definite oncology programs done the completion of Phase 2. Frontier volition beryllium eligible to person success-based improvement and commercialized milestone payments that could perchance transcend $1 billion, successful summation to royalty payments connected commercialized products. AbbVie retains the close to grow the collaboration successful the aboriginal by exercising options to a defined fig of further targets. The collaboration excludes each of Frontier's interior programs for which Frontier retains exclusive planetary rights.
About Frontier Medicines
Frontier Medicines is simply a precision medicine institution that has pioneered a almighty cause find engine, The Frontier™ Platform, designed to make medicines against disease-causing proteins antecedently considered undruggable. The institution is deploying its technologies successful chemoproteomics, covalent cause discovery, and instrumentality learning to perchance make groundbreaking medicines for genetically-defined diligent populations, starting successful cancer. Frontier is advancing its wholly-owned pipeline of precision medicines against the astir important drivers of cancer. The company's pb programme straight inhibits some the activated and inactive forms of KRASG12C. For much accusation connected however Frontier is boldly advancing subject to decision disease, sojourn www.frontiermeds.com and travel america connected LinkedIn and Twitter.
About AbbVie
AbbVie's ngo is to observe and present innovative medicines that lick superior wellness issues contiguous and code the aesculapian challenges of tomorrow. We strive to person a singular interaction connected people's lives crossed respective cardinal therapeutic areas: immunology, oncology, neuroscience, oculus care, virology, women's wellness and gastroenterology, successful summation to products and services crossed its Allergan Aesthetics portfolio. For much accusation astir AbbVie, delight sojourn america astatine www.abbvie.com. Follow @abbvie connected Twitter, Facebook, Instagram, YouTube and LinkedIn.
Investor and Media Relations Contact:
Victoria Fort
VP, Corporate Affairs
202.361.0445
victoria.fort@frontiermeds.com
English (US)